011000.KO GeneOne Life Science Inc
- Market cap
- KRW 9.71B
- P/E
- -
- P/B
- 1.36x
- ROE
- -119.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 011000.KO undervalued?
Graham numberThe Graham number of GeneOne Life Science Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GeneOne Life Science Inc fundamental analysis
No fundamental analysis for GeneOne Life Science Inc yet.
GeneOne Life Science Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company's nucleic ac…
Full company profileGeneOne Life Science Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GeneOne Life Science Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 31.4B | 27.2B | 34.3B | 41.2B | 41.5B | 38.7B | 48.7B | 40.2B | 35.7B | 23.9B | 9.27B |
| Gross Profit | 8.10B | 5.66B | 10.7B | 12.9B | 11.4B | 8.76B | 9.34B | -7.76B | -10.9B | -21.4B | -13.9B |
| Operating Income | -14.0B | -24.9B | -11.3B | -8.21B | -18.5B | -27.5B | -40.1B | -48.4B | -43.0B | -42.4B | -30.3B |
| EBITDA | -12.0B | -20.3B | -9.05B | -1.82B | -13.6B | -6.54B | -25.3B | -63.7B | -28.6B | -28.6B | -23.8B |
| Net Income | -15.6B | -23.7B | -11.9B | -7.62B | -18.6B | -16.0B | -38.2B | -77.8B | -48.5B | -47.7B | -42.7B |
| EPS | -11,656 | -17,252 | -7,360 | -5,304 | -6,472 | -5,371 | -12,309 | -25,006 | -15,271 | -13,953 | -2,353 |
| Balance Sheet | |||||||||||
| Total Assets | 65.7B | 45.6B | 49.3B | 51.2B | 137B | 249B | 223B | 151B | 151B | 119B | 124B |
| Total Liabilities | 29.8B | 9.09B | 19.9B | 27.1B | 38.1B | 44.0B | 41.4B | 39.5B | 65.7B | 78.3B | 88.7B |
| Shareholders' Equity | 35.9B | 36.5B | 29.4B | 24.1B | 98.5B | 207B | 181B | 111B | 85.6B | 40.9B | 35.7B |
| Cash & Short-term Investments | 38.3B | 22.6B | 22.7B | 17.5B | 90.5B | 107B | 45.6B | 9.99B | 1.75B | 3.21B | 444M |
| Total Debt | 22.1B | 1.46B | 12.4B | 14.5B | 17.8B | 18.4B | 19.7B | 17.2B | 27.1B | 33.0B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.4B | -4.04B | -7.27B | -1.27B | -15.9B | -4.85B | -24.1B | -21.7B | -16.1B | -16.5B | -15.8B |
| Capital Expenditure | 2.13B | 413M | 3.64B | 3.01B | 16.4B | 82.5B | 45.4B | 5.65B | 3.37B | 23.8M | 0.00 |
| Free Cash Flow | -14.5B | -4.45B | -10.9B | -4.28B | -32.3B | -87.4B | -69.5B | -27.4B | -19.4B | -16.5B | -15.8B |
| Ratios | |||||||||||
| ROE | -43.5% | -64.9% | -40.5% | -31.7% | -18.9% | -7.7% | -21.0% | -69.8% | -56.7% | -116.5% | -119.5% |
| ROA | -23.8% | -52.0% | -24.1% | -14.9% | -13.7% | -6.4% | -17.1% | -51.5% | -32.1% | -40.0% | -34.3% |
| Net Profit Margin | -49.7% | -87.3% | -34.7% | -18.5% | -44.9% | -41.2% | -78.3% | -193.4% | -135.9% | -199.2% | -460.0% |
| Debt to Equity | 0.62x | 0.04x | 0.42x | 0.60x | 0.18x | 0.09x | 0.11x | 0.15x | 0.32x | 0.81x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
GeneOne Life Science Inc dividends
GeneOne Life Science Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 0.2:1 on Jun 25, 2026.
Who owns GeneOne Life Science Inc
- Insiders 2.28%
- Institutions 7.56%
- Public & others 90.16%
- Shares outstanding 18.2M
- Free float 16.5M
GeneOne Life Science Inc company profile
- Company name
- GeneOne Life Science Inc
- Ticker
- 011000.KO
- ISIN
- KR7011000007
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Textiles, Apparel & Luxury Goods
- Employees
- 30
- Fiscal year end
- December
- Address
- Parc.1 NH Finance Tower, Seoul, South Korea, 07335
- Phone
- 82 2 3458 4030
- Website
- genels.com
About GeneOne Life Science Inc
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company's nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C re-infection prophylaxis, as well as GLS-6100 that is in pre-clinical stage for hepatitis C prophylaxis. Further, the company's discovery and optimization stage pipeline comprise GLS-7000 for the treatment of breast cancer; GLS-7100 for treating hemophilia A; GLS-8000 for the prevention of chronic hepatitis B; and GLS-8100 for treating rheumatoid arthritis. Additionally, it engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.
GeneOne Life Science Inc management
6- Mr. Young-Keun Park J.D., M.B.A.Director · born 1964
- Mr. Byung-Mun Cho B.A., M.B.A.Executive VP & Executive Director · born 1960
- WooGeun HanCo-Chief Executive Officer
- Kyungjin KimCo-Chief Executive Officer
- Jaekyung Chae B.A.Director of Finance & Accounting Division
- Joel N. Maslow M.B.A., M.D., Ph.D.Chief Medical Officer